The bi-partisan delegation, lead by now former Senate President Keith Faber, received a briefing by P-Cure CEO Dr. Michael Marash on the benefits of proton therapy and the solution P-Cure has developed to substantially reduce the capital costs of developing proton centers, to
increase patient access to the cancer treating benefits of proton therapy, and to increase proton therapy’s clinical efficacy and safety through our patient centric approach.
The delegation came to Israel in November to explore new technology developments. The nine Senators meet with the P-Cure team, toured the offices and facilities in Lod, and were briefed on the advantages of treating patients in a seated position within a gantry-less proton center.
Ohio currently has two proton centers at University Hospital in Cleveland, and at the Cincinnati Children’s Hospital. Yet, with 20 proton centers operating in the US, only about one percent of patients who can benefit from proton therapy have access to this beneficial treatment option.
The Senator’s where briefed that the P-Cure solution can significantly reduce both technology and construction costs, permitting more diverse access to proton therapy through smaller oncology centers in the US and world-wide.
The Jewish Federations of North America hosted the Senatorial visit. In addition to then Senate President Keith Faber, the delegation included Senator Kevin Bacon, Senator Bob Peterson, Senate Majority Whip Gayle Manning, Senator Bill Beagle, Senator Frank LaRose, Senator Cliff Hite, Senator Sandra Williams, and Senator Cecil Thomas.
P-Cure brings a paradigm-changing solution to cancer care for proton patients. Our mission is to provide a comprehensive clinical solution designed for precise treatment planning and delivery, to expand proton therapy access through significantly more affordable proton facilities, and to be committed to compassionate care for patients being treated for cancer. P-Cure puts the patient first. If you’re considering offering proton therapy to patients, See P-Cure First.